openPR Logo

Press Releases from SuppreMol GmbH (1 total)

SuppreMol employs Protagen biomarkers in SLE study

Munich and Dortmund, Germany, August 2, 2011. SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, today announced a collaboration to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE). “We will use the unique biomarker portfolio of Protagen for the rapid identification of autoantibody signatures in the

Go To Page:   1 2 3 4 5 6 7 8 9 10